Digital ambition and commercial reality in pharma

Across pharma, commercial teams recognise that digital capability is a core priority. Websites, platforms, portals, and omnichannel ecosystems now sit at the centre of how brands engage healthcare professionals (HCPs), communicate value, and support adoption.

Yet despite significant investment, many teams still feel that digital is not delivering the impact it promised.

Recently, we’ve had conversations with commercial and digital leaders across several global pharma organisations that reveal a consistent pattern: the challenge is rarely ambition. Instead, it lies in how digital products are structured, scaled, and embedded within commercial strategy.

The difference between incremental progress and meaningful impact often comes down to digital maturity.

In most large organisations, digital ecosystems have grown organically over time. 

Individual brands, therapy areas, markets and more, launch websites, tools, and campaigns to meet immediate needs.

Over time, this has created countless disconnected digital assets.

Experiences vary widely in quality and usability. Platforms are rebuilt in different markets. Content is duplicated. Data lives in multiple systems that rarely speak to each other.

The result is not a lack of digital activity, but a lack of coherence.

What does this mean for commercial teams?

For commercial teams, this fragmentation has consequences. Launch timelines slow down as teams rebuild existing solutions. Costs increase as similar platforms are commissioned repeatedly. Most importantly, HCPs encounter inconsistent experiences across brands and regions.

Digital becomes harder to trust internally and less useful externally.

Many leaders described digital initiatives being treated as isolated projects rather than evolving products. 

Once launched, they often receive limited iteration, little shared learning, and minimal long-term investment.

This project mindset prevents digital capabilities from compounding over time.

A second challenge lies in how digital success is evaluated.

Commercial teams are frequently asked to justify digital investment through direct ROI metrics. Yet leaders consistently noted that the relationship between digital activity and sales impact is rarely linear.

Digital channels typically contribute incremental influence rather than dramatic shifts in prescribing behaviour. The effect may be distributed across awareness and engagement over time.

What does this mean for commercial teams?

When success is framed only in terms of short-term revenue attribution, digital initiatives can appear underwhelming. As budgets tighten, they are often the first investments to face scrutiny.

However, many leaders argue that this framing misses the broader strategic value digital provides.

Speed of launch, consistency of experience, competitive differentiation, and quality of engagement are often far more meaningful indicators of commercial impact.

These signals are harder to measure, but they more accurately reflect how digital supports brand growth.

Even when digital experiences reach HCPs, attention cannot be assumed.

Clinicians operate in an environment saturated with information. Time is limited, and pharma is rarely considered the primary source of clinical truth.

Many HCPs instinctively cross-check information through journals, peers, and independent resources.

What does this mean for commercial teams?

In this context, digital experiences must work harder to earn trust. More content does not solve the problem. Instead, clarity, credibility, and practical usefulness become the defining factors of engagement.

If accessing information is slow, complex, or poorly structured, even valuable data may be ignored.

For commercial teams, this means digital success increasingly depends on experience design rather than simply content distribution.

Personalisation is another area where expectations often differ from reality.

Many organisations have invested heavily in segmentation models and automated campaigns. Yet these systems frequently produce generic, system-driven communication that struggles to resonate with HCPs.

In contrast, human interactions, particularly through field representatives, remain highly effective.

What does this mean for commercial teams?

This highlights an important distinction. Digital should enable personal engagement rather than attempt to replace it.

True personalisation emerges when digital tools support representatives with relevant insights, contextual content, and timely prompts that strengthen human conversations.

The goal is not automation for its own sake, but better coordination between digital channels and human expertise.

Despite these challenges, clear signals of digital maturity are emerging across the industry.

Mature organisations treat digital products as scalable capabilities rather than isolated initiatives.

Instead of building new tools repeatedly, they invest in shared systems and reusable components.

Design systems, shared data structures, and modular platforms allow teams to launch experiences faster while maintaining consistency.

Governance structures support quality and compliance without creating excessive bureaucracy. Teams can experiment, and iterate while still operating within regulatory constraints.

Crucially, mature organisations also align digital initiatives directly with commercial outcomes. Digital teams are not positioned as support functions producing assets, but as partners contributing to strategic growth.

Over time, these capabilities compound. Each improvement strengthens the overall ecosystem rather than existing in isolation.

For commercial leaders, the opportunity is not simply to launch more digital initiatives, but to simplify and strengthen the ecosystem that already exists.

Key opportunities include:

Harmonising digital experiences across markets

Many organisations continue to rebuild similar platforms across brands and regions. Shared platforms, design systems, and reusable components can dramatically reduce duplication while ensuring consistent experiences for HCPs.

Designing around real HCP needs

Clinicians are time-poor and selective about where they spend attention. Digital products must prioritise clarity, speed, and usability — making complex scientific information easy to access, explore, and trust.

Enabling practical personalisation

Automation alone rarely creates meaningful engagement. Digital should instead support human interaction by equipping field teams with insights, relevant content, and timely prompts that strengthen conversations with HCPs.

Strengthening digital foundations

Emerging capabilities such as AI and advanced analytics rely on strong data, governance, and platform infrastructure. Investing in these foundations allows organisations to scale what works rather than repeatedly starting from scratch.

Together, these shifts move digital from a collection of disconnected initiatives toward a cohesive commercial capability, one that compounds value over time rather than delivering isolated bursts of activity.

To see how these challenges show up across the industry, explore our one-page visual summary of the key themes emerging from conversations with commercial pharma digital leaders.

Digital Pharma Commercial Challenges 2026